MX2020006654A - Métodos intraductales de tratamiento de trastornos de mama. - Google Patents

Métodos intraductales de tratamiento de trastornos de mama.

Info

Publication number
MX2020006654A
MX2020006654A MX2020006654A MX2020006654A MX2020006654A MX 2020006654 A MX2020006654 A MX 2020006654A MX 2020006654 A MX2020006654 A MX 2020006654A MX 2020006654 A MX2020006654 A MX 2020006654A MX 2020006654 A MX2020006654 A MX 2020006654A
Authority
MX
Mexico
Prior art keywords
macrophages
treatment
breast disorders
intraductal
methods
Prior art date
Application number
MX2020006654A
Other languages
English (en)
Inventor
Steven C Quay
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of MX2020006654A publication Critical patent/MX2020006654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a métodos y composiciones intraductales para tratar sujetos que tienen trastornos de mama; las composiciones comprenden agentes de repolarización y agentes de bloqueo de la polarización capaces de repolarizar macrófagos M2 a macrófagos M1 en el microambiente tumoral, lo que disminuye los macrófagos M2, aumenta los macrófagos M1 y/o aumenta la sensibilidad a la quimioterapia en el sujeto.
MX2020006654A 2017-12-22 2018-12-20 Métodos intraductales de tratamiento de trastornos de mama. MX2020006654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609665P 2017-12-22 2017-12-22
PCT/US2018/066860 WO2019126538A1 (en) 2017-12-22 2018-12-20 Intraductal methods of treatment of breast disorders

Publications (1)

Publication Number Publication Date
MX2020006654A true MX2020006654A (es) 2020-11-06

Family

ID=66995048

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006654A MX2020006654A (es) 2017-12-22 2018-12-20 Métodos intraductales de tratamiento de trastornos de mama.

Country Status (12)

Country Link
US (1) US20210000920A1 (es)
EP (1) EP3727403A4 (es)
JP (1) JP2021506943A (es)
KR (1) KR20200103764A (es)
CN (1) CN111936152A (es)
AU (1) AU2018392692A1 (es)
CA (1) CA3086655A1 (es)
IL (1) IL275543A (es)
MX (1) MX2020006654A (es)
RU (1) RU2020124144A (es)
SG (1) SG11202005944VA (es)
WO (1) WO2019126538A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US20210060052A1 (en) * 2018-03-15 2021-03-04 Atossa Therapeutics, Inc. In situ methods of inducing of immune response
WO2020198622A1 (en) * 2019-03-27 2020-10-01 Navidea Biopharmaceuticals, Inc. Compositions and methods for altering macrophage phenotype
CA3144985A1 (en) * 2019-06-27 2020-12-30 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Hdac6-activated macrophages, compositions, and uses thereof
US20220281986A1 (en) * 2019-07-12 2022-09-08 The Research Foundation For The State University Of New York Compositions and methods to block and bind cxcr4 to modulate cellular function
WO2021048315A1 (en) * 2019-09-11 2021-03-18 Institut Gustave Roussy Use of duox1 inhibitors for treating cancer
US20230404933A1 (en) * 2020-11-06 2023-12-21 Purdue Research Foundation NON-CATIONIC SOFT POLYPHENOL NANOCAPSULES FOR EFFECTIVE SYSTEMIC DELIVERY OF SMALL INTERFERING RNA (siRNA) FOR CANCER TREATMENT
EP4247419A1 (en) 2020-11-18 2023-09-27 Pionyr Immunotherapeutics, Inc. Anti-marco antibodies and uses thereof
CN113288871B (zh) * 2021-05-28 2022-09-16 华中科技大学 用于调控表观遗传与免疫检查点的药物组合物脂质体制剂
CN116966307A (zh) * 2022-04-22 2023-10-31 深圳先进技术研究院 Ampk抑制剂联合hdac抑制剂在制备肿瘤治疗的药物中的应用
WO2024073600A1 (en) * 2022-09-28 2024-04-04 Board Of Regents, The University Of Texas System Compositions and methods for marco inhibition and improved drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
AU2007233155B2 (en) * 2006-03-29 2012-04-26 Scitech Development Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
SG11201502827RA (en) * 2012-11-09 2015-05-28 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation
CN105030792B (zh) * 2015-06-30 2017-08-25 上海交通大学 Desogestrel在制备抗结肠癌/ER阴性的Ah受体阳性的乳腺癌产品中的应用
US11352439B2 (en) * 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
US20180312600A1 (en) * 2015-10-21 2018-11-01 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
WO2017192973A1 (en) * 2016-05-05 2017-11-09 The Board Of Regents Of The University Of Texas System Methods of treating cancers with gpr132 inhibitors

Also Published As

Publication number Publication date
KR20200103764A (ko) 2020-09-02
EP3727403A1 (en) 2020-10-28
EP3727403A4 (en) 2022-01-12
JP2021506943A (ja) 2021-02-22
SG11202005944VA (en) 2020-07-29
CA3086655A1 (en) 2019-06-27
AU2018392692A1 (en) 2020-07-23
CN111936152A (zh) 2020-11-13
RU2020124144A (ru) 2022-01-24
US20210000920A1 (en) 2021-01-07
IL275543A (en) 2020-08-31
RU2020124144A3 (es) 2022-01-24
WO2019126538A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
MX2020006654A (es) Métodos intraductales de tratamiento de trastornos de mama.
MX2019000200A (es) Agentes antiproliferativos basados en pirimidina.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
PH12018502429A1 (en) Antibody molecules for cancer treatment
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
EA202090655A1 (ru) Комбинированные терапевтические средства и их применение
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
EA201992683A1 (ru) Применение антител против b7h3 для лечения злокачественных опухолей в центральной нервной системе
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2017013142A (es) Terapia combinada para tratar cáncer.
EA201991997A1 (ru) Комбинированная терапия
EP4218809A3 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
WO2017123568A3 (en) Methods for the treatment of myeloid derived suppressor cells related disorders
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12016501838A1 (en) Compounds and their methods of use
PH12020500079A1 (en) Novel substituted xanthine derivates